7.13
0.00%
+0.24
Mimedx Group Inc stock is currently priced at $7.13, with a 24-hour trading volume of 574.17K.
It has seen a +0.00% increased in the last 24 hours and a +5.29% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.49 pivot point. If it approaches the $7.10 support level, significant changes may occur.
Previous Close:
$7.37
Open:
$7.41
24h Volume:
574.17K
Market Cap:
$1.06B
Revenue:
$321.48M
Net Income/Loss:
$67.44M
P/E Ratio:
-40.84
EPS:
-0.1746
Net Cash Flow:
$24.62M
1W Performance:
+17.73%
1M Performance:
+5.29%
6M Performance:
+10.16%
1Y Performance:
+28.40%
Mimedx Group Inc Stock (MDXG) Company Profile
Name
Mimedx Group Inc
Sector
Industry
Phone
770 651 9100
Address
1775 West Oak Commons Court, NE, Marietta
Mimedx Group Inc Stock (MDXG) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-27-23 | Initiated | Craig Hallum | Buy |
Oct-13-22 | Initiated | Mizuho | Buy |
Jul-26-21 | Initiated | Northland Capital | Outperform |
Mar-19-21 | Initiated | H.C. Wainwright | Buy |
Mimedx Group Inc Stock (MDXG) Latest News
MIMEDX Announces First Quarter 2024 Operating and Financial Results
GlobeNewswire Inc.
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
GlobeNewswire Inc.
Mizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To Know
Benzinga
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
GlobeNewswire Inc.
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
GlobeNewswire Inc.
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
GlobeNewswire Inc.
Mimedx Group Inc Stock (MDXG) Financials Data
Mimedx Group Inc (MDXG) Revenue 2024
MDXG reported a revenue (TTM) of $321.48 million for the quarter ending December 31, 2023, a +20.03% rise year-over-year.
Mimedx Group Inc (MDXG) Net Income 2024
MDXG net income (TTM) was $67.44 million for the quarter ending December 31, 2023, a +437.99% increase year-over-year.
Mimedx Group Inc (MDXG) Cash Flow 2024
MDXG recorded a free cash flow (TTM) of $24.62 million for the quarter ending December 31, 2023, a +219.65% increase year-over-year.
Mimedx Group Inc (MDXG) Earnings per Share 2024
MDXG earnings per share (TTM) was $0.38 for the quarter ending December 31, 2023, a +215.15% growth year-over-year.
Mimedx Group Inc Stock (MDXG) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Whitlow Ricci S | Chief Operating Officer |
Feb 20 '24 |
Sale |
8.01 |
15,271 |
122,351 |
401,050 |
Whitlow Ricci S | Chief Operating Officer |
Feb 16 '24 |
Sale |
8.07 |
15,493 |
125,075 |
416,321 |
Whitlow Ricci S | Chief Operating Officer |
Feb 15 '24 |
Sale |
8.06 |
15,198 |
122,496 |
431,814 |
Whitlow Ricci S | Chief Operating Officer |
Feb 14 '24 |
Sale |
8.03 |
15,845 |
127,267 |
447,012 |
DOUG RICE | Chief Financial Officer |
Nov 21 '23 |
Buy |
7.16 |
5,000 |
35,786 |
102,200 |
Stein Robert Benjamin | President, Regenerative Med. |
May 16 '23 |
Sale |
5.95 |
10,365 |
61,627 |
317,803 |
Stein Robert Benjamin | President, Regenerative Med. |
May 15 '23 |
Sale |
6.15 |
3,607 |
22,170 |
328,168 |
Carlson Peter M | Chief Financial Officer |
May 10 '23 |
Sale |
5.93 |
5,976 |
35,414 |
656,435 |
Hulse William Frank IV | General Counsel and CAO |
May 10 '23 |
Sale |
5.93 |
5,870 |
34,786 |
456,564 |
Stein Robert Benjamin | President, Regenerative Med. |
May 10 '23 |
Sale |
5.93 |
5,869 |
34,780 |
331,775 |
About Mimedx Group Inc
MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, arterial ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill, a connective tissue matrix derived from placental disc, umbilical cord, and amnion/chorion tissues. Its products have applications in the areas of wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. The company sells its products through direct sales force, independent sales agents, and third party representatives, as well as independent distributors. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Cap:
|
Volume (24h):